World Investment Advisors LLC Purchases 700 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

World Investment Advisors LLC lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 3.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,132 shares of the biotechnology company’s stock after buying an additional 700 shares during the period. World Investment Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $371,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fifth Third Bancorp lifted its stake in shares of Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $52,000. Meeder Asset Management Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares during the period. Finally, nVerses Capital LLC bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at approximately $96,000. Institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Piper Sandler lowered their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright increased their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, Sanford C. Bernstein lowered their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.70.

Arrowhead Pharmaceuticals Stock Down 0.4 %

Shares of ARWR stock opened at $22.27 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $39.83. The stock has a market cap of $2.77 billion, a P/E ratio of -4.44 and a beta of 0.91. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a 50 day simple moving average of $21.06 and a two-hundred day simple moving average of $23.14.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.